MetaVia Inc.
MTVA
주식 순위
#32862
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
주가
$1.30
마지막 동기화: 2026-10-16
시가총액
$8.53M
변동 (1일)
-5.47%
변동 (1년)
-20.55%
국가
US
거래 MetaVia Inc. (MTVA)
카테고리
Healthcare
의 시가총액 MetaVia Inc.(MTVA)
시가총액: $8.53M
October 2026 기준으로 MetaVia Inc.의 시가총액은 $8.53M입니다. 이는 당사 데이터에 따르면 MetaVia Inc.이 세계에서 32862nd번째로 가치 있는 기업임을 의미합니다. 시가총액은 상장된 회사의 발행 주식 총 시장 가치를 의미하며, 일반적으로 회사의 가치를 측정하는 데 사용됩니다.
2016부터 2026까지 MetaVia Inc.의 시가총액 기록
